Literature DB >> 33732706

Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment.

Peijie Wu1,2, Wei Gao2, Miao Su2, Edouard C Nice3, Wenhui Zhang4, Jie Lin4, Na Xie2.   

Abstract

Cancer is a disease which frequently has a poor prognosis. Although multiple therapeutic strategies have been developed for various cancers, including chemotherapy, radiotherapy, and immunotherapy, resistance to these treatments frequently impedes the clinical outcomes. Besides the active resistance driven by genetic and epigenetic alterations in tumor cells, the tumor microenvironment (TME) has also been reported to be a crucial regulator in tumorigenesis, progression, and resistance. Here, we propose that the adaptive mechanisms of tumor resistance are closely connected with the TME rather than depending on non-cell-autonomous changes in response to clinical treatment. Although the comprehensive understanding of adaptive mechanisms driven by the TME need further investigation to fully elucidate the mechanisms of tumor therapeutic resistance, many clinical treatments targeting the TME have been successful. In this review, we report on recent advances concerning the molecular events and important factors involved in the TME, particularly focusing on the contributions of the TME to adaptive resistance, and provide insights into potential therapeutic methods or translational medicine targeting the TME to overcome resistance to therapy in clinical treatment.
Copyright © 2021 Wu, Gao, Su, Nice, Zhang, Lin and Xie.

Entities:  

Keywords:  adaptive resistance; cancer-associated fibroblasts; exosome; hypoxia; immunotherapy; therapeutic resistance; tumor microenvironment; vasculature system

Year:  2021        PMID: 33732706      PMCID: PMC7957022          DOI: 10.3389/fcell.2021.641469

Source DB:  PubMed          Journal:  Front Cell Dev Biol        ISSN: 2296-634X


  364 in total

Review 1.  Therapeutic implications of tumor interstitial acidification.

Authors:  Iryna Kolosenko; Sofia Avnet; Nicola Baldini; Jenny Viklund; Angelo De Milito
Journal:  Semin Cancer Biol       Date:  2017-02-07       Impact factor: 15.707

Review 2.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

Review 3.  Rethinking the war on cancer.

Authors:  Douglas Hanahan
Journal:  Lancet       Date:  2013-12-16       Impact factor: 79.321

4.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.

Authors:  Chih-Hao Chang; Jing Qiu; David O'Sullivan; Michael D Buck; Takuro Noguchi; Jonathan D Curtis; Qiongyu Chen; Mariel Gindin; Matthew M Gubin; Gerritje J W van der Windt; Elena Tonc; Robert D Schreiber; Edward J Pearce; Erika L Pearce
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

Review 5.  NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential.

Authors:  Na Xie; Lu Zhang; Wei Gao; Canhua Huang; Peter Ernst Huber; Xiaobo Zhou; Changlong Li; Guobo Shen; Bingwen Zou
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

6.  Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration.

Authors:  Valbona Luga; Liang Zhang; Alicia M Viloria-Petit; Abiodun A Ogunjimi; Mohammad R Inanlou; Elaine Chiu; Marguerite Buchanan; Abdel Nasser Hosein; Mark Basik; Jeffrey L Wrana
Journal:  Cell       Date:  2012-12-21       Impact factor: 41.582

7.  Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.

Authors:  Stefan Pusch; Sonja Krausert; Viktoria Fischer; Jörg Balss; Martina Ott; Daniel Schrimpf; David Capper; Felix Sahm; Jessica Eisel; Ann-Christin Beck; Manfred Jugold; Viktoria Eichwald; Stefan Kaulfuss; Olaf Panknin; Hartmut Rehwinkel; Katja Zimmermann; Roman C Hillig; Judith Guenther; Luisella Toschi; Roland Neuhaus; Andrea Haegebart; Holger Hess-Stumpp; Markus Bauser; Wolfgang Wick; Andreas Unterberg; Christel Herold-Mende; Michael Platten; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2017-01-25       Impact factor: 15.887

Review 8.  Involvement of Integrin-Activating Peptides Derived from Tenascin-C in Cancer Aggression and New Anticancer Strategy Using the Fibronectin-Derived Integrin-Inactivating Peptide.

Authors:  Motomichi Fujita; Manabu Sasada; Takuya Iyoda; Fumio Fukai
Journal:  Molecules       Date:  2020-07-16       Impact factor: 4.411

9.  Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Authors:  Mark A Socinski; Robert M Jotte; Federico Cappuzzo; Francisco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez-Abreu; Denis Moro-Sibilot; Christian A Thomas; Fabrice Barlesi; Gene Finley; Claudia Kelsch; Anthony Lee; Shelley Coleman; Yu Deng; Yijing Shen; Marcin Kowanetz; Ariel Lopez-Chavez; Alan Sandler; Martin Reck
Journal:  N Engl J Med       Date:  2018-06-04       Impact factor: 91.245

10.  Tumor-associated macrophages (TAMs) as biomarkers for gastric cancer: A review.

Authors:  Meri R Räihä; Pauli A Puolakkainen
Journal:  Chronic Dis Transl Med       Date:  2018-09-03
View more
  26 in total

1.  Multicellular biomarkers of drug resistance as promising targets for glioma precision medicine and predictors of patient survival.

Authors:  Yuting Lu; Yongzhao Shao
Journal:  Cancer Drug Resist       Date:  2022-06-02

2.  pH and Redox-Dual Sensitive Chitosan Nanoparticles Having Methyl Ester and Disulfide Linkages for Drug Targeting against Cholangiocarcinoma Cells.

Authors:  Ju-Il Yang; Hye Lim Lee; Je-Jung Yun; Jungsoo Kim; Kyoung-Ha So; Young-Il Jeong; Dae-Hwan Kang
Journal:  Materials (Basel)       Date:  2022-05-26       Impact factor: 3.748

Review 3.  KRAS: A Druggable Target in Colon Cancer Patients.

Authors:  Francesca Negri; Lorena Bottarelli; Gian Luigi de'Angelis; Letizia Gnetti
Journal:  Int J Mol Sci       Date:  2022-04-08       Impact factor: 6.208

4.  IDP-410: a Novel Therapeutic Peptide that Alters N-MYC Stability and Reduces Angiogenesis and Tumor Progression in Glioblastomas.

Authors:  Ricardo Gargini; Berta Segura-Collar; María Garranzo-Asensio; Rafael Hortigüela; Patricia Iglesias-Hernández; Daniel Lobato-Alonso; Miguel Moreno-Raja; Santiago Esteban-Martin; Juan M Sepúlveda-Sánchez; Laura Nevola; Pilar Sánchez-Gómez
Journal:  Neurotherapeutics       Date:  2022-01-31       Impact factor: 6.088

5.  A Novel Risk Model Based on Lipid Metabolism-Associated Genes Predicts Prognosis and Indicates Immune Microenvironment in Breast Cancer.

Authors:  Zhimin Ye; Shengmei Zou; Zhiyuan Niu; Zhijie Xu; Yongbin Hu
Journal:  Front Cell Dev Biol       Date:  2021-06-14

6.  PER1 Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Ovarian Cancer.

Authors:  Mali Chen; Lili Zhang; Xiaolong Liu; Zhen Ma; Ling Lv
Journal:  Front Genet       Date:  2021-06-17       Impact factor: 4.599

7.  Highly Active Thermophilic L-Asparaginase from Melioribacter roseus Represents a Novel Large Group of Type II Bacterial L-Asparaginases from Chlorobi-Ignavibacteriae-Bacteroidetes Clade.

Authors:  Maria Dumina; Alexander Zhgun; Marina Pokrovskaya; Svetlana Aleksandrova; Dmitry Zhdanov; Nikolay Sokolov; Michael El'darov
Journal:  Int J Mol Sci       Date:  2021-12-20       Impact factor: 5.923

8.  A tumor microenvironment-responsive poly(amidoamine) dendrimer nanoplatform for hypoxia-responsive chemo/chemodynamic therapy.

Authors:  Yingchao Hao; Yue Gao; Yu Fan; Changchang Zhang; Mengsi Zhan; Xueyan Cao; Xiangyang Shi; Rui Guo
Journal:  J Nanobiotechnology       Date:  2022-01-21       Impact factor: 10.435

Review 9.  Dynamic Cancer Cell Heterogeneity: Diagnostic and Therapeutic Implications.

Authors:  Valerie Jacquemin; Mathieu Antoine; Geneviève Dom; Vincent Detours; Carine Maenhaut; Jacques E Dumont
Journal:  Cancers (Basel)       Date:  2022-01-07       Impact factor: 6.639

Review 10.  3D bioprinting: novel approaches for engineering complex human tissue equivalents and drug testing.

Authors:  Judith Hagenbuchner; Daniel Nothdurfter; Michael J Ausserlechner
Journal:  Essays Biochem       Date:  2021-08-10       Impact factor: 8.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.